BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat
The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...
C&EN1 天
Building a better COVID-19 vaccine
One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...